Read Time:8 Second
Shares of Sage Therapeutics Inc. fell more than 18% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
